Next Article in Journal
Determinants of High Breastfeeding Self-Efficacy among Nursing Mothers in Najran, Saudi Arabia
Previous Article in Journal
Effects of Dietary Supplementation of a Microalgae Extract Containing Fucoxanthin Combined with Guarana on Cognitive Function and Gaming Performance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 8
10.3390/nu15081917
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population

by
Qixin Wu
1,†,
Dandan Shi
1,†,
Ting Dong
1,
Zhuolin Zhang
1,
Qingjian Ou
2,
Yujing Fang
2,* and
Caixia Zhang
1,*
1
Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
2
Department of Experimental Research, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou 510060, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2023, 15(8), 1917; https://doi.org/10.3390/nu15081917
Submission received: 29 March 2023 / Revised: 13 April 2023 / Accepted: 13 April 2023 / Published: 15 April 2023
(This article belongs to the Section Nutritional Epidemiology)
Browse Figure
Versions Notes

Abstract

:
The association between circulating saturated fatty acids (SFAs) including very long-chain SFAs (VLCSFAs) and colorectal cancer (CRC) risk has not been clearly established. To investigate the association between serum SFAs and CRC risk in Chinese population, 680 CRC cases and 680 sex and age-matched (5-year interval) controls were recruited in our study. Serum levels of SFAs were detected by gas chromatography. Unconditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between serum SFAs and CRC risk. Results showed that total SFAs were positively associated with the risk of CRC (adjusted OR quartile 4 vs. 1 = 2.64, 95%CI: 1.47–4.74). However, VLCSFAs were inversely associated with CRC risk (adjusted OR quartile 4 vs. 1 = 0.51, 95%CI: 0.36–0.72). Specifically, lauric acid, myristic acid, palmitic acid, heptadecanoic acid, and arachidic acid were positively associated with CRC risk, while behenic acid and lignoceric acid were inversely associated with CRC risk. This study indicates that higher levels of total serum SFAs and lower levels of serum VLCSFAs were associated with an increased risk of CRC in Chinese population. To reduce the risk of CRC, we recommend reducing the intake of foods containing palmitic acid and heptadecanoic acid such as animal products and dairy products, and moderately increasing the intake of foods containing VLCSFAs such as peanuts and canola oil.

Graphical Abstract

1. Introduction

Colorectal cancer (CRC) is the third most prevalent malignancy worldwide, with more than 1.9 million new CRC cases occurring in 2020, representing about one-tenth of cancer cases [1]. The roles of dietary fats and fatty acids in CRC risk have always been issues of interest [2,3]. Recent research revealed that fatty acids play an important role in the development of cancer [4]. Saturated fatty acids (SFAs) have been shown to promote CRC by affecting cancer cells from the susceptibility of cellular membranes to lipid peroxidation [5]. However, SFAs can be obtained not only through dietary intakes, but also synthesized in vivo [6]. The primary product of de novo lipogenesis is palmitic acid (C16:0). Additionally, dietary sources of SFAs are also different. Lauric acid (C12:0) and myristic acid (C14:0) are derived from vegetable oils [7]. Palmitic acid (C16:0) and stearic acid (C18:0) are found mainly in animal products and tropical oils [7]. Heptadecanoic acid (C17:0) is found in dairy products [8], whereas arachidic acid (C20:0), behenic acid (C22:0), and lignoceric acid (C24:0) are found mainly in peanuts, macadamia nuts, and canola oil. Therefore, circulating SFAs combining endogenous and exogenous SFAs can be better used to examine the association between SFAs and diseases [8].
Although circulating SFAs have been suggested to play a promoting role in the development of breast cancer [9,10], prostate cancer [11,12], and hepatocellular carcinoma [13], the association between circulating SFAs and CRC has not been clearly established [2,3,14,15,16]. Some [2,15,16], but not all [3,14], studies reported that total plasma phospholipid or erythrocyte SFAs were positively associated with CRC risk. Moreover, various chain lengths of SFAs may affect CRC differently, as they may differ in dietary sources, endogenous metabolism, and biological activity. Previous studies have examined the association between individual SFAs and CRC [2,3,15,16]. However, the studied individual SFAs were incomplete, and the results were conflicting.
Very long-chain saturated fatty acids (VLCSFAs) have 20 or more carbons. Recent research suggests that VLCSFAs have a deep influence on inflammation resolution and ceramide-induced apoptosis, which could affect tumour growth [17,18]. Some studies found that circulating VLCSFAs were inversely associated with cardiovascular diseases [19,20], diabetes [21], and non-Hodgkin lymphoma [22]. However, no published studies have investigated the association between circulating VLCSFAs and CRC risk.
Most previous studies investigating the association between circulating SFAs and CRC risk were conducted in Western countries or developed countries, where dietary habits differ from Chinese population [2,3,23]. To our knowledge, no study has reported the association between circulating SFAs including VLCSFAs and CRC risk in China. Therefore, to explore different serum levels of SFAs associated with CRC risk, we examined the association of serum concentrations of SFAs including VLCSFAs with CRC risk in Chinese population. We hypothesize that higher levels of serum SFAs are positively associated with CRC risk, while high levels of serum VLCSFAs are inversely associated with CRC risk. The results of our study might help to provide insights into the roles of individual SFAs in CRC risk and provide research evidence for the targeted cancer prevention strategies.

2. Materials and Methods

2.1. Study Design and Study Sample

This case-control study was conducted as part of a research program on dietary and lifestyle factors related to CRC in China. The study design has been described previously [24,25]. Cases with histologically confirmed CRC diagnosis within 3 months have been recruited by Sun Yat-sen University Cancer Centre, Guangzhou, China, from July 2010 to May 2021. Patients without a prior diagnosis of cancer, aged 30–75 years, Guangdong natives, or who have lived in Guangdong Province for more than 5 years were invited to participate in the study. We excluded participants who could not understand or communicate in Mandarin or Cantonese. Totally, 3174 cases were surveyed, and 2833 eligible cases finished the interview, with a response rate of 89.26%. In this study, we randomly selected 680 blood samples from these cases for the measurement of fatty acids.
Controls were selected from two groups. One group was recruited from the Departments of Otorhinolaryngology, Vascular Surgery, and Plastic Surgery in the First Affiliated Hospital, Sun Yat-sen University, during the period of case collection for CRC. They mainly had sudden deafness, chronic otitis media, chronic sinusitis, polyp of the vocal cord, trigeminal neuralgia, varicose veins, orthopaedics, and facial paralysis. There was no evidence that the above diseases were related to dietary causes, so we selected the controls from these departments. The other group was enrolled from residents of the same community via advertisements, written invitations, or referrals from participants. Control subjects had the same inclusion and exclusion criteria as the cases, with the exception that they had no history or diagnosis of CRC. Totally, 2004 controls were recruited, and 1836 blood samples were successfully collected, with a response rate of 91.62%. A total of 680 controls (591 hospital-derived controls and 89 community-derived controls) frequency-matched to the cases on 5-year age and sex were recruited for laboratory measurement.
All participants gave written informed consent, including permission for medical records. This study was approved by the ethical committee of the School of Public Health of Sun Yat-sen University (approval number: 2019-018).

2.2. Data Collection

All participants completed a structured questionnaire about sociodemographic characteristics, lifestyles (e.g., smoking, passive smoking, drinking, and physical activities), family history of cancer in first-degree relatives, and an 81-item semiquantitative food frequency questionnaire (FFQ) with trained interviewers. Relevant clinical information, such as tumour node metastasis (TNM) stage and histological diagnosis were extracted from medical records. Body mass index (BMI) was calculated by dividing weight (kg) by the squared height (m2). Current smoking meant smoking a minimum of one cigarette per day for more than 6 consecutive months [26]. Passive smoking was defined as non-smokers being exposed to other’s tobacco smoke for a minimum of 15 min/day for the past 5 years. Drinking meant having a drink more than once a week in the last year. Working physical activities were classified by the intensity of work as (a) jobless; (b) sedentary; (c) less intensity; (d) moderate intensity; or (e) heavy intensity. Household and leisure-time physical activities were presented as the sum of metabolic equivalent task (MET) [27,28], then MET-hours/week were calculated by multiplying the hours per week spent in each activity and the MET of each activity.
Participants in this analysis completed a validated semiquantitative FFQ that included 81 food items, including food and beverages [29]. The FFQ evaluated the consumption frequencies and the mean intakes of cereal products, soya and soya products, vegetables, fruit, red and processed meat, poultry, fish and other seafood, egg, dairy products, and nuts of each participant during the 12 months before diagnosis for cases or participation in the survey for controls. The validity and reproducibility of FFQ have been demonstrated in the local population by six 3-day dietary records and the FFQ twice at a one-year interval [29], and the FFQ has been applied in previous studies [24,30,31]. The energy-adjusted Pearson correlation coefficients for the FFQ and six 3-day dietary records were 0.34 for total fat, 0.37 for SFAs, and 0.32 for monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs). The correlation coefficients for the reproducibility of the FFQ were 0.61 for total fat, 0.63 for SFAs and MUFAs, and 0.58 for PUFAs [24]. Daily intakes were calculated for each item based on FFQ data. According to the Chinese food composition table, total energy and nutrient intakes were calculated by multiplying the frequency of consumption of each item by the nutrient content of each item and then summing them [32].

2.3. Blood Collection and Measurement of Serum Fatty Acids

About 5 mL of venous fasting blood sample was collected from each participant, and none of these cases had received any treatment or surgery before blood collection. Once arrived at the laboratory, the samples were centrifuged at 3000 rpm for 10 min at 4 °C, and then serum samples were kept at −80 °C until analysis. To ensure that samples were not affected by storage conditions, serum samples from all participants were stored in the same refrigerator.
Serum levels of fatty acids were detected by gas chromatography (GC). Fatty acid methyl esters were extracted by the method previously reported [25,33]. In brief, we added 750 μL of chloroform/methanol (2:1, v/v), 200 μL of physiological saline, and 50 μL of butylated hydroxytoluene ethanol to 50 μL of serum samples and vortexed them for 1 min. The serum samples were centrifuged at 8000 rpm for 5 min at 4 °C, then the organic layer (lower chloroform layer) was transferred to a reaction vial and dried with a nitrogen-blowing apparatus to obtain the extract. Then we added 750 μL of 14% boron trifluoride-methanol solution to the extract, vortexed for 1 min, and sealed the reaction vial at 90 °C for 1.5 h. After the reaction material cooled to room temperature, we added 1 mL of hexane and 0.9% sodium chloride solution and mixed thoroughly for 1 min. The serum samples were centrifuged at 8000 rpm for 5 min at 4 °C, and then the organic layer was extracted and blown dry with nitrogen blowing. Finally, 100 μL of fatty acid methyl esters was added with hexane and transferred to a brown sample vial.
The fatty acid methyl esters were analysed by Agilent 7890A gas chromatography (Santa Clara, CA, USA) on a capillary column DB-23 (Santa Clara, CA, USA). We applied the standard product of fatty acid methyl esters as a standard. Individual fatty acid was validated using a commercial standard with known retention times. The analysers of fatty acids were completely blinded to information on participants, and peaks were calculated automatically. The serum levels of individual fatty acids were presented as the percentage (%) of total fatty acids, and we assumed undetectable levels for fatty acids values with missing data and assigned them a value of zero. To perform quality control, a quality control sample was put in every 50 samples tested, and the quality control samples were repeated every 50 samples. The intra- and inter-assay coefficients of variation ranged from 0.58 to 12.65% and 2.39 to 18.94%, respectively, which were consistent with previous results [14,34,35].
We selected the following fatty acids in this study: lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), heptadecanoic acid (C17:0), stearic acid (C18:0), arachidic acid (C20:0), behenic acid (C22:0), and lignoceric acid (C24:0). We summarized the data into the following two groups: VLCSFAs (C20:0 + C22:0 + C24:0) and total SFAs (C12:0 + C14:0 + C16:0 + C17:0 + C18:0 + C20:0 + C22:0 + C24:0).

2.4. Statistical Analysis

All dietary intakes were adjusted for total energy intake using the residual method [36]. We compared the continuous variables between cases and control using the Wilcoxon rank-sum test, t-test, and the χ2-test for categorical variables. Unconditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between serum SFAs and CRC risk. Serum levels of SFAs were categorized into four levels (Quartile 1–Quartile 4, Q1–Q4) using the quartiles of each fatty acid distribution in the control group for men and women separately, and the Q1 with the lowest serum level was used as the referent group. Trends in the quartiles were tested by assigning each category to its median and using it as a continuous variable in the logistic regression model.
Potential confounders were selected according to the comparison of factors between cases and controls, combined with previous relevant studies. Variables contained in all regression models were as follows: sex, age, residence, type of job, education, marital status, income, working physical activities, household and leisure-time physical activities, smoking, passive smoking, drinking, family history of cancer in first-degree relatives, BMI, total energy intake, dietary red and processed meat intake, dietary calcium intake, dietary fibre intake, serum MUFAs, and serum PUFAs.
Stratified analysis by sex was carried out for the associations between serum SFAs and CRC risk. The interactions between sex and serum SFAs were evaluated by multiplicative models, containing the product term in the multivariable logistic regression models. Moreover, we also conducted subgroup analyses by cancer sites (colon or rectal cancer) and cancer stages (TNM stage I–II or TNM stage III–IV). Heterogeneity in the results between cancer sites or cancer stages was assessed using case-only analyses. Cancer sites or cancer stages were used as the dependent variable and serum SFAs as independent variables in the logistic regression model.
All data analyses were carried out using Stata software version 15.1 (StataCorp, College Station, TX, USA). All p-values were two-sided and considered significant at p < 0.05.

3. Results

Among the 680 cases, there were 350 men and 330 women. In total, 403 were diagnosed with colon cancer and 277 with rectal cancer. There were 343 cases at TNM stage I-II, and 326 cases at TNM stage III-IV. Compared to controls, more cases had a low level of education, high proportions of being married and lower income, and were likely to engage in more physical activities in work. Smoking or passive smoking was more frequent in cases than in controls. The cases tended to have a family history of cancer in first-degree relatives, consume more red and processed meat and less calcium and fibre, and have lower levels of serum PUFAs (Table 1).
Table 2 presents the percentage of serum SFAs in CRC cases and controls. The most abundant SFA in serum was palmitic acid (C16:0) in both cases and controls. Serum levels of total SFAs, lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), heptadecanoic acid (C17:0), stearic acid (C18:0), and arachidic acid (C20:0) were significantly higher in cases than in controls, whereas behenic acid (C22:0), lignoceric acid (C24:0), and VLCSFAs were significantly lower among cases.
As shown in Table 3, total serum SFAs were positively associated with the risk of CRC (adjusted ORQ4 vs. Q1 = 2.64, 95%CI: 1.47–4.74, p-Trend < 0.001). However, serum VLCSFAs were inversely associated with CRC risk (adjusted ORQ4 vs. Q1 = 0.51, 95%CI: 0.36–0.72, p-Trend < 0.001). Regarding the individual SFAs, lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), heptadecanoic acid (C17:0), and arachidic acid (C20:0) were positively associated with the risk of CRC (all p-Trend < 0.05). In contrast, behenic acid (C22:0) and lignoceric acid (C24:0) were inversely associated with CRC risk (all p-Trend < 0.05). However, the association of stearic acid (C18:0) with CRC risk was not statistically significant (p-Trend = 0.108).
Total SFAs were associated with an increased risk of CRC among women (adjusted OR Q4 vs. Q1 = 14.65, 95% CI: 5.60–38.32, p-Trend < 0.001) but not among men (p-Interaction < 0.001) (Table 4). Significant interactions were also observed between sex and serum myristic acid (C14:0), palmitic acid (C16:0), stearic acid (C18:0), arachidic acid (C20:0), and lignoceric acid (C24:0) on the risk of CRC (all p-Interaction < 0.05). In contrast, no significant interaction was observed between sex and serum lauric acid (C12:0), heptadecanoic acid (C17:0), behenic acid (C22:0), and VLCSFAs (all p-Interaction > 0.05). Serum VLCSFAs were inversely associated with CRC risk only in men (OR Q4 vs. Q1 = 0.40, 95% CI: 0.24–0.66, p-Trend < 0.001), but there was no significant interaction (p-Interaction = 0.067).
Subgroup analysis by cancer sites found no statistically significant heterogeneity in CRC risk estimates for total and individual SFAs (all p-Heterogeneity > 0.05) (Table 5), and similar findings were observed for subgroup analysis by cancer stages (all p-Heterogeneity > 0.05) (Table 6).

4. Discussion

This study aimed to investigate the association between serum SFAs including VLCSFAs and CRC risk. The results showed that total SFAs were positively associated with CRC risk, whereas serum VLCSFAs were inversely associated with CRC risk. Specifically, serum levels of lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), heptadecanoic acid (C17:0), and arachidic acid (C20:0) were positively associated with CRC risk, while behenic acid (C22:0) and lignoceric acid (C24:0) were inversely associated with CRC risk.
To our knowledge, no published studies have investigated the association of circulating lauric acid (C12:0) with CRC risk. Our observation of the positive association between lauric acid (C12:0) and CRC risk was supported by a cellular study, which demonstrated that lauric acid induces cyclooxygenase overexpression in human tissues [37]. One study [3] found an inverse association between myristic acid (C14:0) and CRC risk. Three studies [2,15,16] did not find a significant association between myristic acid (C14:0) and CRC risk. These were contrary to our observation of a positive association between myristic acid (C14:0) and CRC risk.
Consistent with our results, two studies [2,15] found that palmitic acid (C16:0) was positively associated with CRC risk. Palmitic acid (C16:0), the predominant SFA in serum, has been found in cellular studies to increase CRC risk by upregulating the endoplasmic reticulum stress response [38] and inducing inflammatory cytokine expression [39]. In addition, palmitic acid (C16:0) has been shown to increase the expression of the β-adrenergic receptors and increase energy production in CRC, thereby promoting CRC development [40]. However, the Singapore Chinese Health Study [41] observed that palmitic acid (C16:0) was inversely associated with colon cancer risk but not associated with rectal cancer risk, and the European Prospective Investigation into Cancer and Nutrition cohort [3] found no significant association between plasma phospholipid palmitic acid (C16:0) and CRC risk.
Heptadecanoic acid (C17:0) is mainly extracted from dairy products, thus heptadecanoic acid (C17:0) can be a biomarker of dairy product consumption [8]. We found a positive association between serum heptadecanoic acid (C17:0) and CRC risk. However, two studies examining the association between heptadecanoic acid (C17:0) and CRC demonstrated a negative association [16] or no significant association [3] between erythrocyte or plasma phospholipid heptadecanoic acid (C17:0) and CRC risk. Considering the relatively low serum level of heptadecanoic acid (C17:0) in our study, further studies are needed to validate the association between heptadecanoic acid (C17:0) and CRC risk. Moreover, no significant association between serum stearic acid (C18:0) and CRC risk in our study was consistent with some previous studies [2,3,15,41]. However, two previous studies found that plasma stearic acid (C18:0) [42] or erythrocyte stearic acid (C18:0) [16] was positively associated with CRC risk.
At present, no other studies have been reported to investigate the association between circulating VLCSFAs and CRC risk. Studies examining the association of VLCSFAs with cardiovascular diseases [19,20,43], diabetes [21], and non-Hodgkin lymphoma [22] have shown beneficial findings. Two studies showed negative associations between plasma/serum lignoceric acid (C24:0) and the risk of pancreatic cancer [44] and prostate cancer [45]. Our findings of inverse associations of serum VLCSFAs, behenic acid (C22:0), and lignoceric acid (C24:0) with the risk of CRC suggest an extension of this evidence to CRC. However, a positive association between arachidic acid (C20:0) and CRC risk observed in our study are conflicting with previous studies that reported an inverse association between circulating arachidic acid (C20:0) and the risk of cardiovascular diseases [19,20,46], diabetes [21], and non-Hodgkin lymphoma [22]. This result needed to be verified. One possible mechanism for the inverse association of VLCSFAs with CRC risk is the activation of proliferator-activated receptor gamma (PPAR-γ) [47]. PPAR-γ is a ligand-activated nuclear receptor of the transcription factor superfamily and is expressed in the colon, which has been shown to significantly inhibit the proliferation and induction of CRC in vitro [48] and in vivo studies [49]. Another possible mechanism might be the involvement of VLCSFAs in the metabolism of ceramides [17], which might inhibit the development of CRC via activating the apoptosis of colon cancer cells [50,51]. However, the exact mechanism for the negative association of VLCSFAs with CRC risk remains to be elucidated.
Positive associations of total serum SFAs with CRC risk were consistent with some previous studies. A case-control study in Japan showed that total serum SFAs were positively associated with the risk of colorectal adenoma [52], a precursor lesion of CRC. In addition, total plasma phospholipid SFAs [2] or total erythrocyte SFAs [15,16] were reported to be positively associated with CRC risk. However, some studies found no significant association between total plasma phospholipid SFAs [3] or total serum SFAs [14] and CRC risk. Furthermore, our results were consistent with some studies examining the association between dietary SFAs and CRC risk. A case-control study in Korea found a positive association between dietary SFAs and CRC risk [53]. An ecological study showed that a diet high in animal fats and SFAs was associated with an increased risk of CRC [54]. The positive association of SFAs with CRC risk might be related to the activation of orphan G protein-coupled receptors (GPCRs) termed free fatty acid receptors (FFARs). FFAR4 (GPR120) is a receptor for medium- and long-chain fatty acids [55]. In vitro studies reported that the activation of FFAR4 signaling pathways promotes motile activity and angiogenesis in colon cancer cells [56]. Additionally, it has been reported that SFAs may promote CRC by affecting the sensitivity of cellular membranes to lipid peroxidation [5].
Total serum SFAs were found to be associated with an increased risk of CRC among women, but not among men, which is consistent with the Singapore Chinese Health Study [57]. One possible explanation is that palmitic acid (C16:0) activates microglia and triggers a strong inflammatory cascade response in which female microglia have a greater basal and stimulated phagocytic activity than male microglia, which may explain the different association of SFAs with CRC risk by sex [58]. Serum VLCSFAs were inversely and significantly associated with CRC risk only in men. The exact explanation for the different results in both sexes is unclear. However, plasma ferritin concentrations increased with VLCSFAs in Chinese men [59], which may lead to iron-catalysed necrosis of tumour cells and thus a negative correlation for the risk of CRC [60]. More studies are required to clarify this finding.
We found no significant heterogeneity in CRC risk estimates for total serum SFAs and individual SFAs by cancer sites. Similarly, we found no significant heterogeneity in CRC risk estimates for total serum SFAs and individual SFAs by cancer stages. No previous studies have evaluated differences between circulating SFAs and the risk of CRC by cancer sites or cancer stages. Due to the small number of cases after stratification in our study, studies with more cases are needed to verify the relationship between circulating SFAs and the risk of CRC by cancer sites or cancer stages.
To our knowledge, this is the first study to examine the association between serum SFAs and CRC risk in China. We used serum SFAs to estimate the link between SFAs and CRC risk, which can directly reflect the association between SFAs in vivo and CRC. Additionally, information on sociodemographic characteristics, lifestyles, and family history of cancer in first-degree relatives was collected and adjusted in multivariable regression models, which could reduce residual confounding as much as possible. Moreover, the levels of total serum SFAs in our study were comparable to the results of some studies among Chinese population [61,62]. A possible reason for this result is the dominant high-carbohydrate diet in the Chinese population [63], which may lead to an upregulation of de novo lipogenesis and an increase in serum palmitic acid (C16:0) [64].
There are some limitations of our study. Firstly, selection bias might occur since the CRC patients we recruited were from the same hospital. However, Sun Yat-sen University Cancer Centre is the largest cancer centre in southern China, and patients with CRC at this centre have similar clinical characteristics to patients from other hospitals in China [65]. Therefore, the results are still somewhat extrapolated. Secondly, we only had a single collection of blood samples, which may not fully represent the information before the diagnosis of CRC. However, it was reported that the changes in circulating odd-chain SFAs and even-chain SFAs over 13 years were only −0.63%/y and −0.05%/y, respectively, and there was no change in VLCSFAs over 13 years [66]. Therefore, we can assume that circulating SFAs and VLCSFAs remained largely unchanged before the diagnosis of CRC. Thirdly, GC analysis was performed at a median of 6.25 years after sample collection, and prolonged storage may affect serum fatty acids’ stability. However, previous studies did not observe significant differences in serum fatty acid composition after 8–10 years of storage at −80 °C [67]. Finally, the results of SFAs may differ from measuring different biological samples. However, previous studies found no significant differences between matched plasma and serum samples for fatty acids content in both absolute and relative values [68], which means that the results of plasma and serum fatty acids are comparable.

5. Conclusions

This study suggests that higher levels of total serum SFAs were associated with an elevated risk of CRC in Chinese population, while higher levels of serum VLCSFAs were associated with a lower risk. Herein, we report the first evidence that higher concentrations of serum VLCSFAs are associated with a lower risk of CRC, and this might provide new insights into the prevention of CRC. Further molecular biology studies are needed to identify the possible mechanisms of the protective roles of VLCSFAs. Since SFAs are either absorbed from dietary sources or derived from de novo fatty acid synthesis [6]; there should be different targeted dietary recommendations for different SFAs. Diets high in carbohydrates can lead to de novo synthesis of palmitic acid [64,69], and dietary palmitic acid is found mainly in animal products [7], thus we should reduce the intake of carbohydrates and animal products. In addition, a moderate reduction in the intake of dairy products should be suggested since heptadecanoic acid is mainly derived from dairy products [8]. Moreover, a moderate increase in the intake of peanuts and canola oil could also be suggested because VLCSFAs are found mainly in peanuts and canola oil. Our findings add to the growing but still limited body of evidence showing the potential differences in the health effects of different types of serum SFAs.

Author Contributions

Q.W. and D.S. contributed equally to this study. Conceptualization, C.Z. and Q.W.; data curation, C.Z.; formal analysis, Q.W.; funding acquisition, C.Z.; investigation, Q.W., D.S., T.D. and Z.Z.; methodology, C.Z., Q.W., D.S., T.D. and Z.Z.; project administration, C.Z.; resources, Y.F. and Q.O.; supervision, C.Z.; visualization, C.Z. and Q.W.; writing—original draft preparation, Q.W. and D.S.; and writing—review and editing, C.Z. and Y.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (No: 81973020 and 81871991) and Guangdong Basic and Applied Basic Research Foundation (No: 2021A1515011751). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement

This study was approved by the ethical committee of the School of Public Health of Sun Yat-sen University (approval number: 2019-018 in February 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study, including permission for medical records.

Data Availability Statement

This is a case-control study, where all anonymized data were obtained from secured electronic medical records. Data sharing is not applicable to this article. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn (accessed on 4 January 2023)), with the approval RDD number RDDA2023386891.

Acknowledgments

We would like to thank all participants and investigators in this study, and we also thank the research staff of Sun Yat-sen University Cancer Centre for their contribution to the data.

Conflicts of Interest

All of the authors declare no conflicts of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Hodge, A.M.; Williamson, E.J.; Bassett, J.K.; MacInnis, R.J.; Giles, G.G.; English, D.R. Dietary and biomarker estimates of fatty acids and risk of colorectal cancer. Int. J. Cancer 2015, 137, 1224–1234. [Google Scholar] [CrossRef] [PubMed]
  3. Aglago, E.K.; Murphy, N.; Huybrechts, I.; Nicolas, G.; Casagrande, C.; Fedirko, V.; Weiderpass, E.; Rothwell, J.A.; Dahm, C.C.; Olsen, A.; et al. Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Int. J. Cancer 2021, 149, 865–882. [Google Scholar] [CrossRef]
  4. Cao, D.; Song, X.; Che, L.; Li, X.; Pilo, M.G.; Vidili, G.; Porcu, A.; Solinas, A.; Cigliano, A.; Pes, G.M.; et al. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int. 2017, 37, 80–89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Rysman, E.; Brusselmans, K.; Scheys, K.; Timmermans, L.; Derua, R.; Munck, S.; Van Veldhoven, P.P.; Waltregny, D.; Daniëls, V.W.; Machiels, J.; et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70, 8117–8126. [Google Scholar] [CrossRef] [Green Version]
  6. Arab, L. Biomarkers of fat and fatty acid intake. J. Nutr. 2003, 133 (Suppl. S3), 925s–932s. [Google Scholar] [CrossRef] [Green Version]
  7. Nkondjock, A.; Shatenstein, B.; Maisonneuve, P.; Ghadirian, P. Specific fatty acids and human colorectal cancer: An overview. Cancer Detect. Prev. 2003, 27, 55–66. [Google Scholar] [CrossRef]
  8. Saadatian-Elahi, M.; Slimani, N.; Chajès, V.; Jenab, M.; Goudable, J.; Biessy, C.; Ferrari, P.; Byrnes, G.; Autier, P.; Peeters, P.H.; et al. Plasma phospholipid fatty acid profiles and their association with food intakes: Results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. Am. J. Clin. Nutr. 2009, 89, 331–346. [Google Scholar] [CrossRef] [Green Version]
  9. Shannon, J.; King, I.B.; Moshofsky, R.; Lampe, J.W.; Gao, D.L.; Ray, R.M.; Thomas, D.B. Erythrocyte fatty acids and breast cancer risk: A case-control study in Shanghai, China. Am. J. Clin. Nutr. 2007, 85, 1090–1097. [Google Scholar] [CrossRef] [Green Version]
  10. Bassett, J.K.; Hodge, A.M.; English, D.R.; MacInnis, R.J.; Giles, G.G. Plasma phospholipids fatty acids, dietary fatty acids, and breast cancer risk. Cancer Causes Control 2016, 27, 759–773. [Google Scholar] [CrossRef]
  11. Crowe, F.L.; Allen, N.E.; Appleby, P.N.; Overvad, K.; Aardestrup, I.V.; Johnsen, N.F.; Tjønneland, A.; Linseisen, J.; Kaaks, R.; Boeing, H.; et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am. J. Clin. Nutr. 2008, 88, 1353–1363. [Google Scholar] [CrossRef] [PubMed]
  12. Bassett, J.K.; Severi, G.; Hodge, A.M.; MacInnis, R.J.; Gibson, R.A.; Hopper, J.L.; English, D.R.; Giles, G.G. Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk. Int. J. Cancer 2013, 133, 1882–1891. [Google Scholar] [CrossRef] [PubMed]
  13. Mouillot, T.; Rizk, M.; Pais de Barros, J.P.; Gilloteau, A.; Busson, A.; Bernard-Chabert, B.; Thiefin, G.; Barraud, H.; Bronowicki, J.P.; Richou, C.; et al. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients. Alimen. Pharmacol. Ther. 2020, 52, 1503–1515. [Google Scholar] [CrossRef] [PubMed]
  14. Kojima, M.; Wakai, K.; Tokudome, S.; Suzuki, K.; Tamakoshi, K.; Watanabe, Y.; Kawado, M.; Hashimoto, S.; Hayakawa, N.; Ozasa, K.; et al. Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: A prospective study. Am. J. Epidemiol. 2005, 161, 462–471. [Google Scholar] [CrossRef] [PubMed]
  15. Kuriki, K.; Wakai, K.; Hirose, K.; Matsuo, K.; Ito, H.; Suzuki, T.; Saito, T.; Kanemitsu, Y.; Hirai, T.; Kato, T.; et al. Risk of colorectal cancer is linked to erythrocyte compositions of fatty acids as biomarkers for dietary intakes of fish, fat, and fatty acids. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1791–1798. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Linseisen, J.; Grundmann, N.; Zoller, D.; Kühn, T.; Jansen, E.H.J.M.; Chajès, V.; Fedirko, V.; Weiderpass, E.; Dahm, C.C.; Overvad, K.; et al. Red Blood Cell Fatty Acids and Risk of Colorectal Cancer in The European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol. Biomark. Prev. 2021, 30, 874–885. [Google Scholar] [CrossRef] [PubMed]
  17. Kihara, A. Very long-chain fatty acids: Elongation, physiology and related disorders. J. Biochem. 2012, 152, 387–395. [Google Scholar] [CrossRef]
  18. Grösch, S.; Schiffmann, S.; Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res. 2012, 51, 50–62. [Google Scholar] [CrossRef]
  19. Liu, M.; Zuo, L.S.; Sun, T.Y.; Wu, Y.Y.; Liu, Y.P.; Zeng, F.F.; Chen, Y.M. Circulating Very-Long-Chain Saturated Fatty Acids Were Inversely Associated with Cardiovascular Health: A Prospective Cohort Study and Meta-Analysis. Nutrients 2020, 12, 2709. [Google Scholar] [CrossRef]
  20. Lemaitre, R.N.; McKnight, B.; Sotoodehnia, N.; Fretts, A.M.; Qureshi, W.T.; Song, X.; King, I.B.; Sitlani, C.M.; Siscovick, D.S.; Psaty, B.M.; et al. Circulating Very Long-Chain Saturated Fatty Acids and Heart Failure: The Cardiovascular Health Study. J. Am. Heart Assoc. 2018, 7, e010019. [Google Scholar] [CrossRef] [Green Version]
  21. Imamura, F.; Sharp, S.J.; Koulman, A.; Schulze, M.B.; Kröger, J.; Griffin, J.L.; Huerta, J.M.; Guevara, M.; Sluijs, I.; Agudo, A.; et al. A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study. PLoS Med. 2017, 14, e1002409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Chiu, Y.H.; Bertrand, K.A.; Zhang, S.; Laden, F.; Epstein, M.M.; Rosner, B.A.; Chiuve, S.; Campos, H.; Giovannucci, E.L.; Chavarro, J.E.; et al. A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma. Int. J. Cancer 2018, 143, 1914–1922. [Google Scholar] [CrossRef] [Green Version]
  23. Shen, X.; Fang, A.; He, J.; Liu, Z.; Guo, M.; Gao, R.; Li, K. Trends in dietary fat and fatty acid intakes and related food sources among Chinese adults: A longitudinal study from the China Health and Nutrition Survey (1997–2011). Public Health Nutr. 2017, 20, 2927–2936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Zhong, X.; Fang, Y.J.; Pan, Z.Z.; Li, B.; Wang, L.; Zheng, M.C.; Chen, Y.M.; Zhang, C.X. Dietary fat, fatty acid intakes and colorectal cancer risk in Chinese adults: A case-control study. Eur. J. Cancer Prev. 2013, 22, 438–447. [Google Scholar] [CrossRef] [PubMed]
  25. Shi, D.D.; Fang, Y.J.; Jiang, Y.L.; Dong, T.; Zhang, Z.L.; Ma, T.; Zhou, R.L.; Ou, Q.J.; Zhang, C.X. Serum levels of n-3 PUFA and colorectal cancer risk in Chinese population. Br. J. Nutr. 2023; 1–11, online ahead of print. [Google Scholar] [CrossRef]
  26. World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic; World Health Organization: Geneva, Switzerland, 1998. [Google Scholar]
  27. Ainsworth, B.E.; Haskell, W.L.; Whitt, M.C.; Irwin, M.L.; Swartz, A.M.; Strath, S.J.; O’Brien, W.L.; Bassett, D.R., Jr.; Schmitz, K.H.; Emplaincourt, P.O.; et al. Compendium of physical activities: An update of activity codes and MET intensities. Med. Sci. Sport. Exerc. 2000, 32, S498–S504. [Google Scholar] [CrossRef] [Green Version]
  28. Ainsworth, B.E.; Haskell, W.L.; Herrmann, S.D.; Meckes, N.; Bassett, D.R., Jr.; Tudor-Locke, C.; Greer, J.L.; Vezina, J.; Whitt-Glover, M.C.; Leon, A.S. 2011 Compendium of Physical Activities: A second update of codes and MET values. Med. Sci. Sport. Exerc. 2011, 43, 1575–1581. [Google Scholar] [CrossRef] [Green Version]
  29. Zhang, C.X.; Ho, S.C. Validity and reproducibility of a food frequency Questionnaire among Chinese women in Guangdong province. Asia Pac. J. Clin. Nutr. 2009, 18, 240–250. [Google Scholar]
  30. Huang, J.; Fang, Y.J.; Xu, M.; Luo, H.; Zhang, N.Q.; Huang, W.Q.; Pan, Z.Z.; Chen, Y.M.; Zhang, C.X. Carbohydrate, dietary glycaemic index and glycaemic load, and colorectal cancer risk: A case-control study in China. Br. J. Nutr. 2018, 119, 937–948. [Google Scholar] [CrossRef] [Green Version]
  31. Luo, H.; Fang, Y.J.; Lu, M.S.; Pan, Z.Z.; Huang, J.; Chen, Y.M.; Zhang, C.X. Dietary and serum vitamins A and E and colorectal cancer risk in Chinese population: A case-control study. Eur. J. Cancer Prev. 2019, 28, 268–277. [Google Scholar] [CrossRef]
  32. Yang, Y.X.; Wang, G.Y.; Pan, X.C. China Food Composition; Peking University Medical Press: Beijing, China, 2002. [Google Scholar]
  33. Folch, J.; Lees, M.; Sloane Stanley, G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497–509. [Google Scholar] [CrossRef] [PubMed]
  34. Takata, Y.; King, I.B.; Neuhouser, M.L.; Schaffer, S.; Barnett, M.; Thornquist, M.; Peters, U.; Goodman, G.E. Association of serum phospholipid fatty acids with breast cancer risk among postmenopausal cigarette smokers. Cancer Causes Control 2009, 20, 497–504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Yaemsiri, S.; Sen, S.; Tinker, L.F.; Robinson, W.R.; Evans, R.W.; Rosamond, W.; Wasserthiel-Smoller, S.; He, K. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013, 44, 2710–2717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic studies. Am. J. Clin. Nutr. 1997, 65, 1220S–1228S, discussion 1229S–1231S. [Google Scholar] [CrossRef] [Green Version]
  37. Lee, J.Y.; Sohn, K.H.; Rhee, S.H.; Hwang, D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001, 276, 16683–16689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Piccolis, M.; Bond, L.M.; Kampmann, M.; Pulimeno, P.; Chitraju, C.; Jayson, C.B.K.; Vaites, L.P.; Boland, S.; Lai, Z.W.; Gabriel, K.R.; et al. Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. Mol. Cell 2019, 74, 32–44.e38. [Google Scholar] [CrossRef] [Green Version]
  39. Ghezzal, S.; Postal, B.G.; Quevrain, E.; Brot, L.; Seksik, P.; Leturque, A.; Thenet, S.; Carrière, V. Palmitic acid damages gut epithelium integrity and initiates inflammatory cytokine production. Biochim. Biophys. Acta. Mol. Cell. Biol. Lipids 2020, 1865, 158530. [Google Scholar] [CrossRef]
  40. Fatima, S.; Hu, X.; Huang, C.; Zhang, W.; Cai, J.; Huang, M.; Gong, R.H.; Chen, M.; Ho, A.H.M.; Su, T.; et al. High-fat diet feeding and palmitic acid increase CRC growth in β2AR-dependent manner. Cell Death Dis. 2019, 10, 711. [Google Scholar] [CrossRef] [Green Version]
  41. Butler, L.M.; Yuan, J.M.; Huang, J.Y.; Su, J.; Wang, R.; Koh, W.P.; Ong, C.N. Plasma fatty acids and risk of colon and rectal cancers in the Singapore Chinese Health Study. NPJ Precis. Oncol. 2017, 1, 38. [Google Scholar] [CrossRef] [Green Version]
  42. May-Wilson, S.; Sud, A.; Law, P.J.; Palin, K.; Tuupanen, S.; Gylfe, A.; Hänninen, U.A.; Cajuso, T.; Tanskanen, T.; Kondelin, J.; et al. Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. Eur. J. Cancer 2017, 84, 228–238. [Google Scholar] [CrossRef] [Green Version]
  43. Fretts, A.M.; Mozaffarian, D.; Siscovick, D.S.; Djousse, L.; Heckbert, S.R.; King, I.B.; McKnight, B.; Sitlani, C.; Sacks, F.M.; Song, X.; et al. Plasma phospholipid saturated fatty acids and incident atrial fibrillation: The Cardiovascular Health Study. J. Am. Heart Assoc. 2014, 3, e000889. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Shu, X.; Zheng, W.; Yu, D.; Li, H.L.; Lan, Q.; Yang, G.; Cai, H.; Ma, X.; Rothman, N.; Gao, Y.T.; et al. Prospective metabolomics study identifies potential novel blood metabolites associated with pancreatic cancer risk. Int. J. Cancer 2018, 143, 2161–2167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Harvei, S.; Bjerve, K.S.; Tretli, S.; Jellum, E.; Robsahm, T.E.; Vatten, L. Prediagnostic level of fatty acids in serum phospholipids: Omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int. J. Cancer 1997, 71, 545–551. [Google Scholar] [CrossRef]
  46. Papandreou, C.; Sala-Vila, A.; Galié, S.; Muralidharan, J.; Estruch, R.; Fitó, M.; Razquin, C.; Corella, D.; Ros, E.; Timiraos, J.; et al. Association Between Fatty Acids of Blood Cell Membranes and Incidence of Coronary Heart Disease. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 819–825. [Google Scholar] [CrossRef] [PubMed]
  47. Kobayashi, T.; Fujimori, K. Very long-chain-fatty acids enhance adipogenesis through coregulation of Elovl3 and PPARγ in 3T3-L1 cells. Am. J. Physio. Endocrinol. Metab. 2012, 302, E1461–E1471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Ban, J.O.; Kwak, D.H.; Oh, J.H.; Park, E.J.; Cho, M.C.; Song, H.S.; Song, M.J.; Han, S.B.; Moon, D.C.; Kang, K.W.; et al. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem.-Biol. Interact. 2010, 188, 75–85. [Google Scholar] [CrossRef]
  49. Osawa, E.; Nakajima, A.; Wada, K.; Ishimine, S.; Fujisawa, N.; Kawamori, T.; Matsuhashi, N.; Kadowaki, T.; Ochiai, M.; Sekihara, H.; et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003, 124, 361–367. [Google Scholar] [CrossRef]
  50. Selzner, M.; Bielawska, A.; Morse, M.A.; Rüdiger, H.A.; Sindram, D.; Hannun, Y.A.; Clavien, P.A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001, 61, 1233–1240. [Google Scholar]
  51. Guo, W.; Zhang, C.; Feng, P.; Li, M.; Wang, X.; Xia, Y.; Chen, D.; Li, J. M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis. Oncogene 2021, 40, 5913–5924. [Google Scholar] [CrossRef]
  52. Ghadimi, R.; Kuriki, K.; Tsuge, S.; Takeda, E.; Imaeda, N.; Suzuki, S.; Sawai, A.; Takekuma, K.; Hosono, A.; Tokudome, Y.; et al. Serum concentrations of fatty acids and colorectal adenoma risk: A case-control study in Japan. Asian Pac. J. Cancer Prev. 2008, 9, 111–118. [Google Scholar]
  53. Chun, Y.J.; Sohn, S.K.; Song, H.K.; Lee, S.M.; Youn, Y.H.; Lee, S.; Park, H. Associations of colorectal cancer incidence with nutrient and food group intakes in korean adults: A case-control study. Clin. Nutr. Res. 2015, 4, 110–123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Reddy, B.S. Omega-3 fatty acids in colorectal cancer prevention. Int. J. Cancer 2004, 112, 1–7. [Google Scholar] [CrossRef] [PubMed]
  55. Kimura, I.; Ichimura, A.; Ohue-Kitano, R.; Igarashi, M. Free Fatty Acid Receptors in Health and Disease. Physiol. Rev. 2020, 100, 171–210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Takahashi, K.; Fukushima, K.; Onishi, Y.; Minami, K.; Otagaki, S.; Ishimoto, K.; Fukushima, N.; Honoki, K.; Tsujiuchi, T. Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells. Exp. Cell Res. 2018, 369, 54–60. [Google Scholar] [CrossRef]
  57. Butler, L.M.; Wang, R.; Koh, W.P.; Stern, M.C.; Yuan, J.M.; Yu, M.C. Marine n-3 and saturated fatty acids in relation to risk of colorectal cancer in Singapore Chinese: A prospective study. Int. J. Cancer 2009, 124, 678–686. [Google Scholar] [CrossRef] [Green Version]
  58. Yanguas-Casás, N.; Crespo-Castrillo, A.; de Ceballos, M.L.; Chowen, J.A.; Azcoitia, I.; Arevalo, M.A.; Garcia-Segura, L.M. Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic acid. Glia 2018, 66, 522–537. [Google Scholar] [CrossRef]
  59. Li, Z.; Li, X.; Zhang, Y.; Feng, X.; Yang, F.; Su, D.; Qiu, J.; Ling, W.; Yang, Y. Erythrocyte membrane fatty acid composition is related to overloaded plasma ferritin in Chinese males with angiographic coronary artery disease. Food Funct. 2013, 4, 1535–1542. [Google Scholar] [CrossRef]
  60. Hassannia, B.; Vandenabeele, P.; Vanden Berghe, T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 2019, 35, 830–849. [Google Scholar] [CrossRef]
  61. Zhao, L.; Hao, F.; Huang, J.; Liu, X.; Ma, X.; Wang, C.; Bao, Y.; Wang, L.; Jia, W.; Zhao, A.; et al. Sex- and Age-Related Metabolic Characteristics of Serum Free Fatty Acids in Healthy Chinese Adults. J. Proteome Res. 2020, 19, 1383–1391. [Google Scholar] [CrossRef]
  62. Yu, Y.; Cai, Z.; Zheng, J.; Chen, J.; Zhang, X.; Huang, X.F.; Li, D. Serum levels of polyunsaturated fatty acids are low in Chinese men with metabolic syndrome, whereas serum levels of saturated fatty acids, zinc, and magnesium are high. Nutr. Res. 2012, 32, 71–77. [Google Scholar] [CrossRef]
  63. Zhai, F.; Wang, H.; Du, S.; He, Y.; Wang, Z.; Ge, K.; Popkin, B.M. Prospective study on nutrition transition in China. Nutr. Rev. 2009, 67 (Suppl. S1), S56–S61. [Google Scholar] [CrossRef] [PubMed]
  64. King, I.B.; Lemaitre, R.N.; Kestin, M. Effect of a low-fat diet on fatty acid composition in red cells, plasma phospholipids, and cholesterol esters: Investigation of a biomarker of total fat intake. Am. J. Clin. Nutr. 2006, 83, 227–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Li, Z.F.; Huang, H.Y.; Shi, J.F.; Guo, C.G.; Zou, S.M.; Liu, C.C.; Wang, Y.; Wang, L.; Zhu, S.L.; Wu, S.L.; et al. A systematic review of worldwide natural history models of colorectal cancer: Classification, transition rate and a recommendation for developing Chinese population-specific model. Zhonghua Liu Xing Bing Xue Za Zhi 2017, 38, 253–260. [Google Scholar] [PubMed]
  66. Zheng, J.S.; Imamura, F.; Sharp, S.J.; Koulman, A.; Griffin, J.L.; Mulligan, A.A.; Luben, R.; Khaw, K.T.; Wareham, N.J.; Forouhi, N.G. Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study. Am. J. Clin. Nutr. 2019, 109, 1527–1534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Matthan, N.R.; Ip, B.; Resteghini, N.; Ausman, L.M.; Lichtenstein, A.H. Long-term fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. J. Lipid Res. 2010, 51, 2826–2832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Buchanan, C.D.C.; Lust, C.A.C.; Burns, J.L.; Hillyer, L.M.; Martin, S.A.; Wittert, G.A.; Ma, D.W.L. Analysis of major fatty acids from matched plasma and serum samples reveals highly comparable absolute and relative levels. Prostaglandins Leukot. Essent. Fatty Acids 2021, 168, 102268. [Google Scholar] [CrossRef]
  69. Hudgins, L.C.; Hellerstein, M.; Seidman, C.; Neese, R.; Diakun, J.; Hirsch, J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J. Clin. Investig. 1996, 97, 2081–2091. [Google Scholar] [CrossRef]
Table
Table 1. Sociodemographic characteristics and selected risk factors of colorectal cancer in the study population.
Table 1. Sociodemographic characteristics and selected risk factors of colorectal cancer in the study population.
Cases (n = 680)Controls (n = 680)p-Value 1
Age, years, mean ± SD53.69 ± 10.7153.25 ± 10.600.456
Women, n (%)330 (48.53)336 (49.41)0.745
Urban, n (%)455 (66.91)487 (71.62)0.060
Type of job, n (%) 0.242
Administrator/other white-collar workers112 (16.47)131 (19.26)
Blue-collar worker192 (28.24)170 (25.00)
Farmer/others376 (55.29)379 (55.74)
Education, n (%) <0.001
Primary school or lower194 (28.53)177 (26.03)
Secondary school200 (29.41)166 (24.41)
High school174 (25.59)157 (23.09)
University or above112 (16.47)180 (26.47)
Married, n (%)645 (94.85)622 (91.47)0.013
Income, Yuan/month, n (%) 0.002
≤200098 (14.41)133 (19.56)
2001–5000207 (30.44)171 (25.15)
5001–8000208 (30.59)176 (25.88)
>8000167 (24.56)200 (29.41)
Working physical activities, n (%) 0.019
Jobless113 (16.62)114 (16.76)
Sedentary180 (26.47)221 (32.50)
Less intensity187 (27.50)164 (24.12)
Moderate intensity96 (14.12)66 (9.71)
Heavy intensity104 (15.29)115 (16.91)
Smoking, n (%) <0.001
Never431 (63.38)484 (71.18)
Current184 (27.06)112 (16.47)
Former65 (9.56)84 (12.35)
Passive smoking, n (%)185 (27.21)129 (18.97)<0.001
Drinking, n (%)104 (15.29)110 (16.18)0.655
Family history of cancer in first-degree relatives, n (%)98 (14.41)69 (10.15)0.017
BMI, kg/m2, mean ± SD23.28 ± 3.3123.60 ± 3.160.067
Household and leisure-time physical activities, MET-hours/week, mean ± SD32.47 ± 28.4435.28 ± 31.090.081
Total energy intake, kcal/day, median (P25, P75)1483.93 (1197.49, 1825.80)1465.65 (1232.38, 1762.89)0.907
Dietary red and processed meat intake, g/day, median (P25, P75) 2109.20 (75.58, 144.61)99.51 (75.41, 136.68)0.044
Dietary calcium intake, mg/day, median (P25, P75) 2361.35 (283.93, 448.67)418.81 (329.80, 535.22)<0.001
Dietary fibre intake, g/day, median (P25, P75) 28.27 (6.77, 10.02)9.52 (7.60, 11.41)<0.001
Serum MUFAs, %, median (P25, P75)16.00 (14.55, 17.60)15.80 (14.14, 17.66)0.180
Serum PUFAs, %, median (P25, P75)28.04 (25.49, 30.32)31.00 (28.47, 33.58)<0.001
Site, n (%)
Colon403 (59.26)--
Rectal277 (40.74)--
TNM stage, n (%)
Stage I–II343 (50.44)--
Stage III–IV326 (47.94)--
Unknown11 (1.62)--
Abbreviations: BMI, body mass index; MET, metabolic equivalent task; MUFAs, monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; SD, standard deviation. 1 Wilcoxon rank-sum test or t-test was used for continuous variables. χ2-test was used for categorical variables. 2 Dietary intakes were adjusted for total energy intake using the residual method.
Table
Table 2. Percentage of serum saturated fatty acids in colorectal case and control subjects.
Table 2. Percentage of serum saturated fatty acids in colorectal case and control subjects.
% of Total Fatty AcidsCases (n = 680)Controls (n = 680)p-Value 1
MeanMedian (P25, P75)MeanMedian (P25, P75)
Lauric acid (C12:0, %)1.911.88 (1.41, 2.34)1.671.66 (1.24, 2.05)<0.001
Myristic acid (C14:0, %)0.260.15 (0.11, 0.27)0.200.13 (0.10, 0.19)<0.001
Palmitic acid (C16:0, %)34.1133.90 (32.48, 35.53)32.4532.10 (30.40, 34.08)<0.001
Heptadecanoic acid (C17:0, %)0.630.37 (0.31, 0.50)0.430.34 (0.29, 0.40)<0.001
Stearic acid (C18:0, %)16.5816.49 (15.18, 18.04)15.5615.44 (14.10, 16.89)<0.001
Arachidic acid (C20:0, %)0.310.28 (0.24, 0.34)0.270.26 (0.22, 0.30)<0.001
Behenic acid (C22:0, %)0.330.26 (0.19, 0.39)0.420.34 (0.24, 0.48)<0.001
Lignoceric acid (C24:0, %)0.350.30 (0.23, 0.40)0.390.34 (0.27, 0.45)<0.001
VLCSFAs (%)0.990.90 (0.73, 1.11)1.080.98 (0.82, 1.20)<0.001
Total SFAs (%)51.9351.37 (49.17, 54.38)49.2948.59 (45.72, 52.14)<0.001
Abbreviations: SFAs, saturated fatty acids; VLCSFAs, very long-chain saturated fatty acids. 1 Wilcoxon rank-sum test was used to compare median levels of SFAs between cases and controls.
Table
Table 3. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids.
Table 3. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids.
Q1Q2Q3Q4p-Trend
Lauric acid (C12:0)
Number of cases/controls140/170109/170160/170271/170
Model 1 1 1.00 0.78 (0.56–1.08)1.14 (0.84–1.56)1.94 (1.44–2.60)<0.001
Model 2 21.00 1.25 (0.85–1.83)1.52 (1.06–2.17)1.94 (1.38–2.74)<0.001
Myristic acid (C14:0)
Number of cases/controls134/170134/170206/170206/170
Model 1 11.001.00 (0.73–1.38)1.54 (1.13–2.08)1.54 (1.13–2.08)<0.001
Model 2 21.000.97 (0.67–1.40)1.31 (0.92–1.86)1.34 (0.93–1.95)0.049
Palmitic acid (C16:0)
Number of cases/controls64/17077/170164/170375/170
Model 1 11.001.20 (0.81–1.78)2.56 (1.79–3.67)5.86 (4.17–8.23)<0.001
Model 2 21.001.03 (0.66–1.60)1.97 (1.26–3.05)3.61 (2.14–6.10)<0.001
Heptadecanoic acid (C17:0)
Number of cases/controls117/170157/170138/170268/170
Model 1 11.001.34 (0.97–1.85)1.18 (0.85–1.63)2.29 (1.69–3.10)<0.001
Model 2 21.001.50 (1.04–2.17)1.15 (0.79–1.67)2.35 (1.64–3.35)<0.001
Stearic acid (C18:0)
Number of cases/controls98/170110/170154/170318/170
Model 1 11.001.12 (0.79–1.59)1.57 (1.13–2.19)3.24 (2.38–4.43)<0.001
Model 2 21.001.13 (0.75–1.71)1.20 (0.78–1.84)1.52 (0.92–2.52)0.108
Arachidic acid (C20:0)
Number of cases/controls120/170118/170179/170263/170
Model 1 11.000.98 (0.71–1.37)1.49 (1.09–2.04)2.19 (1.62–2.97)<0.001
Model 2 21.001.11 (0.76–1.62)1.61 (1.12–2.31)2.30 (1.60–3.30)<0.001
Behenic acid (C22:0)
Number of cases/controls280/170180/170115/170105/170
Model 1 11.000.64 (0.48–0.85)0.41 (0.30–0.56)0.38 (0.28–0.51)<0.001
Model 2 21.000.72 (0.52–1.00)0.42 (0.30–0.60)0.43 (0.30–0.60)<0.001
Lignoceric acid (C24:0)
Number of cases/controls275/170154/170121/170130/170
Model 1 11.000.56 (0.42–0.75)0.44 (0.33–0.59)0.47 (0.35–0.64)<0.001
Model 2 21.000.72 (0.52–1.00)0.56 (0.40–0.80)0.58 (0.41–0.81)<0.001
VLCSFAs
Number of cases/controls279/170129/170144/170128/170
Model 1 11.000.46 (0.34–0.62)0.52 (0.39–0.69)0.46 (0.34–0.62)<0.001
Model 2 21.000.59 (0.42–0.83)0.60 (0.43–0.84)0.51 (0.36–0.72)<0.001
Total SFAs
Number of cases/controls71/17092/170178/170339/170
Model 1 11.001.29 (0.88–1.88)2.49 (1.76–3.53)4.75 (3.40–6.62)<0.001
Model 2 21.001.12 (0.72–1.73)1.79 (1.13–2.84)2.64 (1.47–4.74)<0.001
Abbreviations: Q, quartile; CIs, confidence intervals; ORs, odds ratios; SFAs, saturated fatty acids; VLCSFAs, very long-chain saturated fatty acids. 1 Crude OR (95% CI). 2 Adjusted for sex, age, residence, type of job, education, marital status, income, working physical activities, household and leisure-time physical activities, smoking, passive smoking, drinking, family history of cancer in first-degree relatives, BMI, total energy intake, dietary red and processed meat intake, dietary calcium intake, dietary fibre intake, serum MUFAs, and serum PUFAs.
Table
Table 4. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids by sex.
Table 4. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids by sex.
Women (n = 330)Men (n = 350)p-Interaction
Q1Q4 1p-TrendQ1Q4 1p-Trend
Lauric acid (C12:0)
Number of cases/controls58/84145/84 82/86126/86
Adjusted OR (95% CI) 2 1.002.72 (1.63–4.56)<0.0011.001.65 (0.99–2.74)0.0610.138
Myristic acid (C14:0)
Number of cases/controls42/84165/84 92/8641/86
Adjusted OR (95% CI) 2 1.004.59 (2.53–8.32)<0.0011.000.39 (0.22–0.68)0.029<0.001
Palmitic acid (C16:0)
Number of cases/controls12/84224/84 52/86151/86
Adjusted OR (95% CI) 2 1.0013.05 (5.52–30.85)<0.0011.001.77 (0.81–3.85)0.065<0.001
Heptadecanoic acid (C17:0)
Number of cases/controls66/84104/84 51/86164/86
Adjusted OR (95% CI) 2 1.001.40 (0.83–2.37)0.5301.003.88 (2.29–6.57)<0.0010.056
Stearic acid (C18:0)
Number of cases/controls21/84192/84 77/86126/86
Adjusted OR (95% CI) 2 1.005.16 (2.30–11.58)<0.0011.000.70 (0.33–1.46)0.164<0.001
Arachidic acid (C20:0)
Number of cases/controls38/84147/84 82/86116/86
Adjusted OR (95% CI) 2 1.005.41 (3.02–9.68)<0.0011.001.55 (0.93–2.58)0.0530.006
Behenic acid (C22:0)
Number of cases/controls142/8446/84 138/8659/86
Adjusted OR (95% CI) 2 1.000.40 (0.23–0.67)<0.0011.000.46 (0.28–0.77)<0.0010.963
Lignoceric acid (C24:0)
Number of cases/controls121/8484/84 154/8646/86
Adjusted OR (95% CI) 2 1.000.88 (0.54–1.43)0.3781.000.29 (0.17–0.50)<0.0010.043
VLCSFAs
Number of cases/controls115/8470/84 164/8658/86
Adjusted OR (95% CI) 2 1.000.66 (0.40–1.11)0.2031.000.40 (0.24–0.66)<0.0010.067
Total SFAs
Number of cases/controls11/84203/84 60/86136/86
Adjusted OR (95% CI) 2 1.0014.65 (5.60–38.32)<0.0011.000.90 (0.36–2.28)0.876<0.001
Abbreviations: Q, quartile; CIs, confidence intervals; ORs, odds ratios; SFAs, saturated fatty acids; VLCSFAs, very long-chain saturated fatty acids. 1 The table provided data for the highest quartile (Q4) and the lowest quartile (Q1) only. 2 Adjusted for age, residence, type of job, education, marital status, income, working physical activities, household and leisure-time physical activities, smoking, passive smoking, drinking, family history of cancer in first-degree relatives, BMI, total energy intake, dietary red and processed meat intake, dietary calcium intake, dietary fibre intake, serum MUFAs, and serum PUFAs.
Table
Table 5. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids by cancer sites.
Table 5. Odds ratios (ORs) and 95% confidence intervals (CIs) of colorectal cancer according to quartiles of serum saturated fatty acids by cancer sites.
Colon Cancer (n = 403) Rectal Cancer (n = 277)p-Heterogeneity
Q1Q4 1p-TrendQ1Q4 1p-Trend
Lauric acid (C12:0)
Number of cases/controls91/170159/170 49/170112/170
Adjusted OR (95% CI) 21.001.82 (1.23–2.69)0.0021.002.21 (1.39–3.49)0.0010.454
Myristic acid (C14:0)
Number of cases/controls85/170121/170 49/17085/170
Adjusted OR (95% CI) 21.001.25 (0.82–1.92)0.1901.001.59 (0.97–2.61)0.0230.229
Palmitic acid (C16:0)
Number of cases/controls35/170239/170 29/170136/170
Adjusted OR (95% CI) 21.003.21 (1.72–5.98)<0.0011.003.73 (1.95–7.14)<0.0010.502
Heptadecanoic acid (C17:0)
Number of cases/controls73/170166/170 44/170102/170
Adjusted OR (95% CI) 21.002.29 (1.52–3.45)<0.0011.002.32 (1.44–3.74)0.0040.310
Stearic acid (C18:0)
Number of cases/controls51/170189/170 47/170129/170
Adjusted OR (95% CI) 21.001.44 (0.79–2.62)0.2371.002.05 (1.09–3.86)0.0300.098
Arachidic acid (C20:0)
Number of cases/controls74/170150/170 46/170113/170
Adjusted OR (95% CI) 21.002.17 (1.43–3.31)<0.0011.002.47 (1.54–3.98)<0.0010.426
Behenic acid (C22:0)
Number of cases/controls174/17060/170 106/17045/170
Adjusted OR (95% CI) 21.000.38 (0.25–0.58)<0.0011.000.49 (0.31–0.78)<0.0010.398
Lignoceric acid (C24:0)
Number of cases/controls170/17077/170 105/17053/170
Adjusted OR (95% CI) 21.000.60 (0.41–0.90)0.0021.000.59 (0.38–0.92)0.0200.595
VLCSFAs
Number of cases/controls173/17074/170 106/17054/170
Adjusted OR (95% CI) 21.000.50 (0.34–0.76)0.0011.000.57 (0.37–0.89)0.0250.444
Total SFAs
Number of cases/controls38/170215/170 33/170124/170
Adjusted OR (95% CI) 21.002.65 (1.34–5.26)0.0011.002.93 (1.44–5.96)0.0020.786
Abbreviations: Q, quartile; CIs, confidence intervals; ORs, odds ratios; SFAs, saturated fatty acids; VLCSFAs, very long-chain saturated fatty acids. 1 The table provided data for the highest quartile (Q4) and the lowest quartile (Q1) only. 2 Adjusted for sex, age, residence, type of job, education, marital status, income, working physical activities, household and leisure-time physical activities, smoking, passive smoking, drinking, family history of cancer in first-degree relatives, BMI, total energy intake, dietary red and processed meat intake, dietary calcium intake, dietary fibre intake, serum MUFAs, and serum PUFAs.
Table
Table 6. Odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal cancer according to quartiles of serum saturated fatty acids by cancer stages.
Table 6. Odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal cancer according to quartiles of serum saturated fatty acids by cancer stages.
Stage I–II (n = 343)Stage III–IV (n = 326)p-Heterogeneity
Q1Q4 1p-TrendQ1Q4 1p-Trend
Lauric acid (C12:0)
Number of cases/controls76/170135/170 64/170131/170
Adjusted OR (95% CI) 2 1.001.79 (1.19–2.70)0.0041.00 2.02 (1.33–3.08)0.0010.799
Myristic acid (C14:0)
Number of cases/controls66/170100/170 67/170102/170
Adjusted OR (95% CI) 21.001.44 (0.91–2.28)0.0751.001.28 (0.81–2.01)0.0920.845
Palmitic acid (C16:0)
Number of cases/controls31/170170/170 32/170196/170
Adjusted OR (95% CI) 21.003.00 (1.55–5.78)<0.0011.004.07 (2.18–7.59)<0.0010.894
Heptadecanoic acid (C17:0)
Number of cases/controls62/170135/170 54/170126/170
Adjusted OR (95% CI) 21.002.37 (1.54–3.65)<0.0011.002.16 (1.38–3.37)0.0020.831
Stearic acid (C18:0)
Number of cases/controls48/170154/170 49/170159/170
Adjusted OR (95% CI) 21.002.03 (1.10–3.74)0.0151.001.36 (0.73–2.54)0.3620.059
Arachidic acid (C20:0)
Number of cases/controls63/170129/170 56/170128/170
Adjusted OR (95% CI) 21.002.36 (1.52–3.67)<0.0011.00 2.28 (1.46–3.56)<0.0010.743
Behenic acid (C22:0)
Number of cases/controls141/17049/170 135/17055/170
Adjusted OR (95% CI) 21.00 0.43 (0.28–0.67)<0.0011.00 0.41 (0.26–0.63)<0.0010.923
Lignoceric acid (C24:0)
Number of cases/controls136/17063/170 135/17065/170
Adjusted OR (95% CI) 21.000.58 (0.38–0.88)0.0051.000.55 (0.36–0.84)0.0020.836
VLCSFAs
Number of cases/controls141/17059/170 134/17066/170
Adjusted OR (95% CI) 21.000.53 (0.35–0.81)0.0011.000.51 (0.33–0.77)0.0060.318
Total SFAs
Number of cases/controls35/170159/170 35/170173/170
Adjusted OR (95% CI) 21.003.12 (1.54–6.32)<0.0011.002.43 (1.20–4.90)0.0070.283
Abbreviations: Q, quartile; CIs, confidence intervals; ORs, odds ratios; SFAs, saturated fatty acids; VLCSFAs, very long-chain saturated fatty acids. 1 The table provided data for the highest quartile (Q4) and the lowest quartile (Q1) only. 2 Adjusted for sex, age, residence, type of job, education, marital status, income, working physical activities, household and leisure-time physical activities, smoking, passive smoking, drinking, family history of cancer in first-degree relatives, BMI, total energy intake, dietary red and processed meat intake, dietary calcium intake, dietary fibre intake, serum MUFAs, and serum PUFAs.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wu, Q.; Shi, D.; Dong, T.; Zhang, Z.; Ou, Q.; Fang, Y.; Zhang, C. Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population. Nutrients 2023, 15, 1917. https://doi.org/10.3390/nu15081917

AMA Style

Wu Q, Shi D, Dong T, Zhang Z, Ou Q, Fang Y, Zhang C. Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population. Nutrients. 2023; 15(8):1917. https://doi.org/10.3390/nu15081917

Chicago/Turabian Style

Wu, Qixin, Dandan Shi, Ting Dong, Zhuolin Zhang, Qingjian Ou, Yujing Fang, and Caixia Zhang. 2023. "Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population" Nutrients 15, no. 8: 1917. https://doi.org/10.3390/nu15081917

APA Style

Wu, Q., Shi, D., Dong, T., Zhang, Z., Ou, Q., Fang, Y., & Zhang, C. (2023). Serum Saturated Fatty Acids including Very Long-Chain Saturated Fatty Acids and Colorectal Cancer Risk among Chinese Population. Nutrients, 15(8), 1917. https://doi.org/10.3390/nu15081917

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop